Insights Into Infections and Inflammation in Prostate Cancer Development and Management: An Overview

Area of Science:

• Oncology
• Urology
• Immunology

Background:

• Prostate cancer (PCa) is a leading cause of cancer mortality in men, with increasing incidence.
• Established risk factors do not fully explain PCa development, highlighting the need for novel insights.
• Chronic inflammation, particularly infection-associated, is increasingly recognized as a key factor in prostate tumorigenesis.

Purpose of the Study:

• To review epidemiological and experimental evidence linking infection-associated inflammation to PCa.
• To identify key inflammatory signaling pathways involved in prostate cancer initiation and progression.
• To discuss potential therapeutic strategies targeting these inflammatory pathways for PCa management.

Main Methods:

• Systematic review of current epidemiological findings.
• Synthesis of experimental evidence on inflammation and PCa.
• Analysis of signaling pathways including NF-κB, STAT3, COX-2/PGE2, IL-6/IL-8, TLRs, and NLRP3 inflammasome.

Main Results:

• Chronic inflammation from prostatitis, BPH, UTIs, STIs, and catheterization is linked to malignant transformation.
• Prostate microbiome alterations may sustain inflammatory signaling, promoting tumor growth.
• Specific inflammatory pathways (NF-κB, STAT3, COX-2/PGE2, IL-6/IL-8, TLRs, NLRP3) are implicated in PCa.

Conclusions:

• Infection-driven chronic inflammation is a significant contributor to prostate cancer development.
• Modulating specific inflammatory pathways presents promising therapeutic targets for PCa.
• Understanding these interactions can lead to improved PCa biomarkers, risk stratification, and treatment.